Clinical Trial Update: Study of Intravenous NRX-1074 in Patients With Major Depressive Disorder [Phase 2]

View source ↗

Summary

Phase 2 study of intravenous NRX-1074 in major depressive disorder has completed; no efficacy results are provided in the snippet.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• NRX-1074 (NRX-1074)

Snippet

Sponsor: Naurex, Inc, an affiliate of Allergan plc | Conditions: Major Depressive Disorder | Phase 2 | Status: COMPLETED